Gallahue Kieran's Form 4 filing
Edwards Lifesciences Corp (EW) · filed Feb 26, 2024
- Accession no.
- 0001225208-24-002963
- Filed
- Feb 26, 2024
- Trade date
- Feb 23, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $267.9K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gallahue KieranCIK 0001308428 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 23, 2024 | Common Stock | MOption exerciseAcquired | +7,056 | $36.86 | +$260,084.16 | 10,757 | Direct | |
| Feb 23, 2024 | Common Stock | GGiftDisposed | −7,056 | $0.00 | $0 | 3,701 | Direct | |
| Feb 23, 2024 | Common Stock | GGiftAcquired | +7,056 | $0.00 | $0 | 70,277 | Indirect | |
| Feb 23, 2024 | Common Stock | SSaleDisposed | −3,058 | $87.61F1 | −$267,911.38 | 67,219 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 23, 2024 | Common Stock | MOption exerciseDisposed | −7,056 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction was executed in multiple trades at prices ranging from $87.5908 to $87.6210. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.